Trial Condition(s):

Carcinoma, Hepatocellular

Refametinib in combination with sorafenib in RAS mutant Hepatocellular Carcinoma (HCC)

Bayer Identifier:

16728

ClinicalTrials.gov Identifier:

NCT01915602

EudraCT Number:

2013-000241-39

Study Completed

Trial Purpose

This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages. Approximately 95 patients (15 at Stage 1/ 80 at Stage 2) will be accrued to this study to receive treatment. Stage 2 of the trial will only be conducted if at least 5 out of 15 patients at Stage 1 show at least partial response according to an objective criteria to evaluate tumor size based on contrast enhancement [modified response evaluation criteria in solid tumors (mRECIST)] assessed by external independent radiologists.
Refametenib is an oral (i.e. taken by mouth) protein kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, refametinib in combination with sorafenib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning.
The primary endpoint (the most meaningful result to be tracked) of this study is based on the rate of response, i.e. the disease getting smaller. The aim is to show that the therapy with refametinib in combination with sorafenib improves the response rate in this patient population compared to historical results observed with the sorafenib only.

Inclusion Criteria
Eligibility criteria for RAS mutation testing
 - Unresectable or metastatic HCC, confirmed either by histology or clinically according to the American Association for the Study of Liver Disease (AASLD) criteria for cirrhotic patients. For non-cirrhotic patients, histological confirmation is mandatory.
 - Male or female ≥18 years of age.
 - Eastern Cooperative Oncology Group (ECOG) performance state 0 or 1.
 - Life expectancy of at least 12 weeks.
 - No prior use of targeted agents, experimental therapy or systemic anti-cancer treatment.
 - No previous treatment with sorafenib or refametinib.
Criteria for study treatment eligibility
 - Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog (KRAS) or Neuroblastoma RAS viral oncogene homolog (NRAS) mutation based on Beads, emulsions, amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma test.
 - Patients must have at least one uni-dimensional measurable lesion by Computed tomography (CT) or Magnetic resonance (MR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Modified Response Evaluation Criteria in Solid Tumors (mRECIST) which is either naïve (not previously treated by local therapy such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously treated and has progressed until baseline (both measureable lesion and/or progressed lesion have to be confirmed by central image review of baseline and progression scan).
 - ECOG performance status of 0 or 1.
 - Liver function status of Child-Pugh Class A.
 - Adequate bone morrow, liver, and renal function
 - Patient has within normal range cardiac function confirmed by the enrolling clinical institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
 - Patients who are therapeutically anti-coagulated with an agent such as warfarin or heparin are allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until International normalized ratio (INR) is stable (within Child Pugh class A threshold) based on a measurement at pre-dose, as defined by the local standard of care.
Exclusion Criteria
- Any Cancer curatively treated < 3 years prior to study entry, except cervical carcinoma in situ (CIS), treated basal cell carcinoma, and superficial bladder tumors [Staging: noninvasive papillary tumor (Ta), CIS carcinoma (Tis) and tumor invades lamina propria (T1)].
 - Patients who are eligible for surgery, liver transplantation, ablation or transarterial chemoembolization for HCC.
History of cardiac disease:
- Congestive heart failure New York Heart Association (NYHA) > class 2.
- Unstable angina (angina symptoms at rest, new-onset angina i.e. within the last 3 months) or myocardial infarction (MI) within the past 6 months prior to start of screening.
- Cardiac arrhythmias requiring anti-arrhythmic therapy.
- QTc (corrected QT interval) > 480 ms
- Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management).
 - Ongoing infection > Grade 2 according to National Cancer Institute - Common Toxicity Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03) Hepatitis B is allowed if no active replication (defined as abnormal Alanine aminotransferase [ALT] >2x Upper limit normal [ULN] associated with Hepatitis B virus [HBV] DNA >20,000 IU/mL) is present. Hepatitis C is allowed if no antiviral treatment is required.
 - Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR at Screening to confirm the absence of central nervous system [CNS] disease if patient had symptoms suggestive or consistent with CNS disease).
 - History of interstitial lung disease (ILD).
 - History of hepatic encephalopathy.
 - History of organ allograft, cornea transplantation will be allowed.
 - History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
 - Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.

Trial Summary

Enrollment Goal
14
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Refametinib (BAY86-9766)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Wien, Austria, 1090

Status
Completed
 
Locations

Investigative Site

Singapore, Singapore, 169610

Status
Completed
 
Locations

Investigative Site

Hospitalet de Llobregat, Spain, 08907

Status
Completed
 
Locations

Investigative Site

Oviedo, Spain, 33011

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28007

Status
Completed
 
Locations

Investigative Site

Hong Kong, Hong Kong, China, NA

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28050

Status
Completed
 
Locations

Investigative Site

LYON, France, 69004

Status
Completed
 
Locations

Investigative Site

CAEN CEDEX, France, 14033

Status
Completed
 
Locations

Investigative Site

BORDEAUX, France, 33000

Status
Completed
 
Locations

Investigative Site

PARIS, France, 75012

Status
Completed
 
Locations

Investigative Site

Seoul, South Korea, 06351

Status
Completed
 
Locations

Investigative Site

Seoul, South Korea, 03722

Status
Completed
 
Locations

Investigative Site

Seoul, South Korea, 05505

Status
Completed
 
Locations

Investigative Site

Seoul, South Korea, 08308

Status
Completed
 
Locations

Investigative Site

Taipei, Taiwan, China, 10002

Status
Completed
 
Locations

Investigative Site

London, United Kingdom, SE5 9RS

Status
Completed
 
Locations

Investigative Site

EDEGEM, Belgium, 2650

Status
Completed
 
Locations

Investigative Site

LIEGE, Belgium, 4000

Status
Completed
 
Locations

Investigative Site

Bologna, Italy, 40138

Status
Completed
 
Locations

Investigative Site

Milano, Italy, 20122

Status
Completed
 
Locations

Investigative Site

Roma, Italy, 00168

Status
Completed
 
Locations

Investigative Site

Frankfurt, Germany, 60596

Status
Completed
 
Locations

Investigative Site

Hamburg, Germany, 20246

Status
Completed
 
Locations

Investigative Site

Tübingen, Germany, 72076

Status
Completed
 
Locations

Investigative Site

Magdeburg, Germany, 39120

Status
Completed
 
Locations

Investigative Site

Essen, Germany, 45147

Status
Completed
 
Locations

Investigative Site

Jerusalem, Israel, 9112001

Status
Completed
 
Locations

Investigative Site

Petach Tikva, Israel, 4941492

Status
Completed
 
Locations

Investigative Site

Tel Aviv, Israel, 64239

Status
Completed
 
Locations

Investigative Site

Haifa, Israel, 3109601

Status
Completed
 
Locations

Investigative Site

Chiang Mai, Thailand, 50200

Status
Completed
 
Locations

Investigative Site

Khon Kaen, Thailand, 40002

Status
Completed
 
Locations

Investigative Site

Songkhla, Thailand, 90110

Status
Completed
 
Locations

Investigative Site

Olomouc, Czech Republic, 775 20

Status
Completed
 
Locations

Investigative Site

Hradec Kralove, Czech Republic, 500 05

Status
Completed
 
Locations

Investigative Site

Pecs, Hungary, 7932

Status
Completed
 
Locations

Investigative Site

Zalaegerszeg, Hungary, 8900

Status
Completed
 
Locations

Investigative Site

Istanbul, Turkey, 34349

Status
Completed
 
Locations

Investigative Site

Istanbul, Turkey, 34093

Status
Completed
 
Locations

Investigative Site

Istanbul, Turkey, 34899

Status
Completed
 
Locations

Investigative Site

Mersin, Turkey, 33070

Status
Completed
 
Locations

Investigative Site

Seoul, South Korea, 06591

Status
Completed
 
Locations

Investigative Site

NICE CEDEX 3, France, 06202

Status
Completed
 
Locations

Investigative Site

Chiba-shi, Japan, 260-8677

Status
Completed
 
Locations

Investigative Site

Nagoya, Japan, 466-8560

Status
Completed
 
Locations

Investigative Site

Fukuoka-shi, Japan, 810-8563

Status
Completed
 
Locations

Investigative Site

Osaka, Japan, 534-0021

Status
Completed
 
Locations

Investigative Site

Kyoto, Japan, 606-8507

Status
Completed
 
Locations

Investigative Site

Irima-gun, Japan, 350-0495

Status
Completed
 
Locations

Investigative Site

Bunkyo-ku, Japan, 113-8655

Status
Completed
 
Locations

Investigative Site

Osaka, Japan, 545-8586

Status
Completed
 
Locations

Investigative Site

Yokohama, Japan, 241-8515

Status
Completed
 
Locations

Investigative Site

Itabashi-ku, Japan, 173-8610

Status
Completed
 
Locations

Investigative Site

Daegu, South Korea, 700-721

Status
Completed
 
Locations

Investigative Site

Seoul, South Korea, 110-744

Status
Completed
 
Locations

Investigative Site

SAINT-PRIEST-EN-JAREZ, France, 42270

Status
Completed
 
Locations

Investigative Site

Tainan, Taiwan, China, 736

Status
Completed
 
Locations

Investigative Site

LEUVEN, Belgium, 3000

Status
Completed
 
Locations

Investigative Site

BRUXELLES - BRUSSEL, Belgium, 1070

Status
Completed
 
Locations

Investigative Site

Berlin, Germany, 10967

Status
Completed
 
Locations

Investigative Site

VANDOEUVRE-LES-NANCY, France, 54511

Status
Completed
 
Locations

Investigative Site

MARSEILLE, France, 13005

Status
Completed
 
Locations

Investigative Site

Birmingham, United Kingdom, B15 2TH

Status
Completed
 
Locations

Investigative Site

Heidelberg, Germany, 69120

Status
Completed
 
Locations

Investigative Site

Debrecen, Hungary, 4032

Status
Completed
 
Locations

Investigative Site

Budapest, Hungary, 1062

Status
Completed
 
Locations

Investigative Site

Osakasayama-shi, Japan, 589-8511

Status
Completed
 
Locations

Investigative Site

Bern, Switzerland, 3010

Status
Completed
 
Locations

Investigative Site

Auckland, New Zealand, 1023

Status
Completed
 
Locations

Investigative Site

Milano, Italy, 20133

Status
Completed
 
Locations

Investigative Site

Vigo, Spain, 36071

Status
Completed
 
Locations

Investigative Site

Santiago de Compostela, Spain, 15706

Status
Completed
 
Locations

Investigative Site

Tainan, Taiwan, China, 704

Status
Completed
 
Locations

Investigative Site

Louisville, United States, 40202

Status
Completed
 
Locations

Investigative Site

Hong Kong, Hong Kong, China

Status
Completed
 
Locations

Investigative Site

Essen, Germany, 45136

Status
Completed
 
Locations

Investigative Site

Shanghai, China, 200032

Status
Completed
 
Locations

Investigative Site

Guangzhou, China, 510515

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100071

Status
Completed
 

Trial Design